Investigational senolytic drug combination fact sheet
Dasatinib plus quercetin
Also known as D+Q, DQ senolytic combination
Dasatinib plus quercetin has changed senescence markers in very small human studies. The combination is not approved for aging, and dasatinib carries substantial cancer-drug risks.
Quick answer
Dasatinib plus quercetin is not FDA approved for aging, frailty, fibrosis, kidney disease, or cognitive decline. Early pilot studies show feasibility and biomarker effects—not proven clinical benefit—and dasatinib has serious labeled toxicities.
By the PeptideFactSheets Editorial Team. Claims are source-checked under our editorial policy; clinician review is identified only when a named reviewer is shown.
What is Dasatinib plus quercetin?
Dasatinib is an FDA-approved kinase inhibitor for specific leukemias; quercetin is a plant flavonoid sold in supplements.
Researchers combine them because different senescent cell types may rely on different survival pathways. The experimental combination is a new claim set, not an extension of dasatinib's cancer approval.
Why are people interested in it?
Small studies in diabetic kidney disease and idiopathic pulmonary fibrosis reported changes in senescence markers or feasibility outcomes.
The approach directly tests a central geroscience hypothesis, but the human studies are far too small to establish improved disease or longevity outcomes.
Current regulatory status
The D+Q combination has no FDA-approved senolytic or geroscience use. Dasatinib alone is FDA approved for specific leukemia indications under prescription labeling.
What is it approved for?
No FDA-approved use. Commercial availability, supplement marketing, and clinical research do not equal an FDA-approved medicine.
What is it being studied for?
Evidence snapshot
Human evidence consists of small pilot studies focused on feasibility, safety, physical measures, and senescence biomarkers. There is no adequate trial showing fewer diseases, sustained functional benefit, or longer life.
Potential benefits being researched
- A small diabetic-kidney-disease study reported lower senescent-cell markers after treatment.
- Pulmonary-fibrosis pilots established feasibility but were not designed to prove disease modification.
A mechanism, biomarker, or secondary endpoint is not proof of a meaningful clinical benefit.
Known or possible risks
- Dasatinib labeling describes myelosuppression, bleeding, fluid retention, cardiovascular effects, pulmonary arterial hypertension, severe skin reactions, and major interaction risks.
- Quercetin can add interaction and product-quality uncertainty.
- Intermittent research exposure does not erase the serious pharmacology of an oncology medicine.
What we still do not know
- Whether senescence-marker changes improve any patient-centered outcome
- Which senescent cell types are affected in each human tissue
- Whether benefits could outweigh cancer-drug risks in people without cancer
- Long-term and repeated-course safety
Plain-English takeaway
D+Q is important proof-of-concept geroscience, not an established anti-aging treatment. The presence of an approved cancer drug makes casual wellness framing especially unsafe.
Research and reference links
Use these primary and authoritative sources to verify status and read beyond this summary. A study or registry entry does not by itself prove benefit.
- 1FDA prescribing information: Sprycel
Dasatinib's approved cancer uses, warnings, adverse reactions, and interactions.
- 2D+Q diabetic kidney disease pilot
Very small open-label human study of senescence markers rather than clinical efficacy.
- 3Randomized D+Q pulmonary-fibrosis pilot
Small feasibility and tolerability study not powered for disease benefit.
- 4First-in-human D+Q pulmonary-fibrosis pilot
Open-label pilot with no placebo comparison and major interpretive limits.